Breast cancer prediction. Predictive molecular tests and markers Prädiktion beim Mammakarzinom: Prädiktive molekulare Tests und Signaturen
Schem C, Wenners AS, Van Mackelenbergh M, Heilmann T, Jonat W, Mundhenke C (2013)
Publication Type: Journal article
Publication year: 2013
Journal
Book Volume: 46
Pages Range: 377-381
Journal Issue: 6
DOI: 10.1007/s00129-012-3127-1
Abstract
Individualized therapy in breast cancer has progressed substantially in the last few years. HER2-positive patients in particular have benefitted from the development of various innovative therapies that involve the blockade of signal transduction pathways. However, there are still many women who are over-treated with chemotherapy and who would not need this treatment if their individual risk of recurrence and benefit to be gained from adjuvant chemotherapy were known. Classic prognostic factors are not able to discriminate between patients with good and bad prognosis so as to reduce the group of intermediate-risk patients to an acceptable size, if at all. The individual risk of recurrence might also be an individual-dependent estimation. In this review we describe the present classification of intrinsic subtypes of breast cancer and provide information on current commercially available prognostic and predictive tests for breast cancer patients. © Springer-Verlag Berlin Heidelberg 2013.
Involved external institutions
Germany (DE)How to cite
APA:
Schem, C., Wenners, A.S., Van Mackelenbergh, M., Heilmann, T., Jonat, W., & Mundhenke, C. (2013). Breast cancer prediction. Predictive molecular tests and markers Prädiktion beim Mammakarzinom: Prädiktive molekulare Tests und Signaturen. Gynäkologe, 46(6), 377-381. https://dx.doi.org/10.1007/s00129-012-3127-1
MLA:
Schem, C., et al. "Breast cancer prediction. Predictive molecular tests and markers Prädiktion beim Mammakarzinom: Prädiktive molekulare Tests und Signaturen." Gynäkologe 46.6 (2013): 377-381.
BibTeX: Download